Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes

Document Type : Research Articles


1 Postgraduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, Brazil.

2 Department of Gynecology, and Obstetrics, State University of Campinas, Campinas, Brazil.

3 Postgraduate Program in Biotechnology, Potiguar University, Natal, Brazil.

4 Clinical Cytology and STD Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, PR, Brazil.

5 Department of Clinical Analysis and Toxicology, Federal University of Rio Grande do Norte, Natal, Brazil.

6 Department of Pharmacy, Federal University of Rio Grande do Norte, Natal, Brazil.

7 Hospital Lusíadas Porto and Unidade de Tracto Genital Inferior, Serviço de Ginecologia e Obstetrícia, Centro Hospitalar de São João, Porto, Portugal.

8 Department of Female, Child and Adolescent Health, Federal University of Ceará, Fortaleza, Brazil.


Objective: The aim of the study was to describe the course of IgG/IgA immune response in women immunized with bivalent vaccine and in women non-vaccinated with HPV infection, as well as evaluating the cross-protection against non-vaccine HPV types. Methods: Serum and cervical mucus samples were collected from infected and vaccinated women for HPV detection/genotyping and for detection of IgG/IgA anti-HPV/VLP (Virus-like Particles) by ELISA. Results: The median absorbance detected in serum samples for anti-HPV-IgG antibodies was higher in vaccinated women when compared to HPV infected women (p <0.01), however, the median absorbance in cervical mucus samples for anti-HPV-IgA was higher in infected women when compared to vaccinated women (p <0.01). Additionally, our analyses also provided additional evidence for cross-protective efficacy of the HPV-16/18 vaccine against HPV-82, -6, -11, -13, -61, -72 and -74. Conclusion: The IgG antibodies were significantly more detected in the serum of vaccinated women, while the IgA was found in greater quantities in cervical samples from those infected by the virus. In addition, there is evidence that the bivalent vaccine provides cross-protection against other non-oncogenic viral subtypes.


Main Subjects

Volume 21, Issue 9
September 2020
Pages 2799-2804
  • Receive Date: 27 June 2020
  • Revise Date: 11 August 2020
  • Accept Date: 26 September 2020
  • First Publish Date: 26 September 2020